Copyright
©The Author(s) 2017.
World J Clin Oncol. Apr 10, 2017; 8(2): 120-134
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.120
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.120
Table 2 Some of the current clinical trials in breast cancer targeted immunotherapy (http://www.cancerresearch.org./cancer-immunotherapy/impacting-all-cancers/breast-cancer)
| Title of clinical trial | Type of breast cancer |
| Phase III clinical trial: NEUVAX: nelipepimut-S or E75NCT01479244 | HER1+ HER2+ |
| Phase II clinical trial: NEUVAX NCTO1570036 | Node positive or TNBC |
| Phase I clinical trial: Pembrolizumab PD1 antibody + dendritic cell vaccine NCTO2479230 | Metastatic breast cancer |
| Phase II trial: Pembrolizumab PD1 antibody + HDAC inhibitor and anti-estrogen therapy NCT02395627 | Breast cancer |
| Phase II first line neo adjuvant trial: Atezolizumab + chemotherapy NCTO2530489 | TNBC |
| Phase I clinical trial: Atezolizumab and HER2 inhibitors NCTO2605915 | HER2+ |
| Phase I/II clinical trial: PDR001(PD1 antibody) | Advanced breast cancer, TNBC |
| Phase I/II clinical trial: MEDI6469 anti OX40 antibody NCTO1642290 | Stage 4 breast cancer (patients with prior failure of hormone or chemotherapy) |
| Pilot study of QBX258 targeting IL-4 and IL-13 NTCO2494206 | Advanced TNBC whose cancer cells make a protein called glycoprotein NMB to which CDX-011 binds |
- Citation: Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 2017; 8(2): 120-134
- URL: https://www.wjgnet.com/2218-4333/full/v8/i2/120.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i2.120